Guardant Health (GH) Peer Comparison
$170.69
$-16.53
(-8.83%)
As on 06-Oct-2026 16:28EDT
Market cap
$23,860 Mln
Revenue (TTM)
$1,183 Mln
P/E Ratio
--
P/B Ratio
55.7
Div. Yield
0 %
Edit
| Guardant Health (GH) | Vaxcyte (PCVX) | Ionis Pharmaceuticals (IONS) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
23,860 | 8,405 | 7,236 | 127,929 | 75,693 |
Revenue ($ Mln) |
1,183 | -- | 874 | 12,624 | 15,535 |
Net Profit ($ Mln) |
-453.44 | -1,064.26 | -564.78 | 4,405.20 | 4,328.70 |
Net Margin (%) |
-38.33 | -- | -64.64 | 34.89 | 27.86 |
RoE (%) |
-- | -39.10 | -121.61 | 22.64 | 13.75 |
Price to Earnings |
-- | -- | -- | 29.50 | 18.18 |
Price-To-Book |
55.67 | 3.05 | 16.60 | 6.46 | 2.60 |
Income Statement ($ Mln)
| Guardant Health (GH) | Vaxcyte (PCVX) | Ionis Pharmaceuticals (IONS) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,183.11 | 0.00 | 873.76 | 12,624.30 | 15,534.70 |
|
Cost of Revenue
|
413.95 | 0.87 | 16.06 | 1,762.80 | 2,352.10 |
|
Gross Profit
|
633.01 | -- | 928.00 | 10,267.50 | 12,242.20 |
|
Operating Expenses
|
1,239.42 | 1,164.43 | 1,452.60 | 5,989.90 | 9,212.50 |
|
Operating Profit (EBIT)
|
-470.26 | -1,165.29 | -594.90 | 4,872.00 | 3,970.10 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
-454.47 | -1,064.26 | -562.09 | 5,274.90 | 5,166.00 |
|
Provision for Tax
|
-1.03 | 0.00 | 0.17 | 869.30 | 837.30 |
|
Profit after Tax (Net Income)
|
-453.44 | -1,064.26 | -564.78 | 4,405.20 | 4,328.70 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Guardant Health (GH) | Vaxcyte (PCVX) | Ionis Pharmaceuticals (IONS) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-222.87 | 2,757.94 | 439.74 | 20,247.90 | 31,711.00 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
1,796.20 | 108.94 | 2,239.48 | 3,237.50 | 4,488.60 |
|
Current Liabilities
|
338.96 | 271.28 | 316.00 | 3,937.90 | 5,530.60 |
|
Total Liabilities
|
2,013.66 | 3,045.97 | 3,523.84 | 26,142.80 | 40,558.70 |
Assets ($ Mln)
| Guardant Health (GH) | Vaxcyte (PCVX) | Ionis Pharmaceuticals (IONS) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
547.66 | 1,585.49 | 503.23 | 14,879.60 | 23,284.00 |
|
Current Assets
|
1,364.64 | 1,552.67 | 2,491.27 | 12,543.70 | 18,446.00 |
|
Total Assets
|
2,013.66 | 3,045.97 | 3,523.84 | 26,142.80 | 40,558.70 |
|
Total Debt*
|
1,697.01 | 115.45 | 2,418.48 | 1,977.60 | 1,986.60 |
|
Net Current Assets
|
1,025.68 | 1,281.39 | 2,175.64 | 8,605.80 | 12,915.40 |
Cashflow ($ Mln)
| Guardant Health (GH) | Vaxcyte (PCVX) | Ionis Pharmaceuticals (IONS) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-184.76 | -655.58 | -268.58 | 3,631.40 | 4,978.90 |
|
Cash Flow from Investing Activities
|
-627.20 | 437.35 | -277.78 | -945.40 | -629.10 |
|
Cash from Financing Activities
|
671.13 | 2.01 | 675.84 | -2,261.30 | -3,715.40 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Guardant Health (GH) | Vaxcyte (PCVX) | Ionis Pharmaceuticals (IONS) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-29.66 | -24.37 | -14.92 | 19.42 | 13.65 |
|
ROE (%)
|
348.42 | -39.10 | -121.61 | 22.64 | 13.75 |
|
ROA (%)
|
-23.73 | -30.99 | -15.70 | 14.80 | 9.71 |
|
EBIT Margin (%)
|
-38.01 | -- | -57.44 | 41.83 | 33.61 |
|
Net Margin (%)
|
-38.33 | -- | -64.64 | 34.89 | 27.86 |
|
Cash Profit Margin (%)
|
0.00 | -- | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Guardant Health (GH) | Vaxcyte (PCVX) | Ionis Pharmaceuticals (IONS) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
42.74 | -- | -7.45 | 10.56 | 9.29 |
|
EBIT Growth (%)
|
-9.76 | -113.26 | -165.20 | 20.31 | 6.31 |
|
Net Profit Growth (%)
|
-9.57 | -94.39 | -110.57 | 21.10 | -2.91 |
|
EPS Growth (%)
|
-4.67 | -81.42 | -87.06 | 22.80 | 1.72 |
|
Book Value Growth (%)
|
31.44 | -15.46 | -23.27 | 19.36 | 7.70 |
Valuation Ratios
| Guardant Health (GH) | Vaxcyte (PCVX) | Ionis Pharmaceuticals (IONS) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-31.57 | -8.19 | -33.64 | 29.37 | 18.42 |
|
Price / Book Value
|
-132.33 | 2.34 | 26.20 | 6.22 | 2.65 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-36.51 | -6.67 | -44.47 | 23.31 | 13.25 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Guardant Health (GH) | Vaxcyte (PCVX) | Ionis Pharmaceuticals (IONS) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-6.74 | 0.00 | 3.07 | 0.00 | 0.06 |
|
Short term debt to equity ratio
|
-0.12 | 0.00 | 0.55 | 0.00 | 0.00 |
|
Current Ratio
|
4.03 | 5.72 | 7.88 | 3.19 | 3.34 |
|
Quick Ratio
|
3.71 | 5.72 | 7.72 | 2.74 | 2.78 |
|
Interest Coverage
|
-93.37 | -- | -5.28 | 800.23 | 94.25 |
Operating Efficiency Ratios
| Guardant Health (GH) | Vaxcyte (PCVX) | Ionis Pharmaceuticals (IONS) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
12.19 | -- | 6.73 | 16.91 | 42.26 |
|
Asset Turnover
|
0.62 | 0.00 | 0.24 | 0.42 | 0.35 |
|
Receivable days
|
46.14 | -- | 30.60 | 55.39 | 152.19 |
|
Inventory Days
|
82.13 | -- | 257.50 | 292.28 | 546.66 |
|
Payable days
|
48.66 | -- | 810.92 | 88.40 | 150.27 |
|
Cash Conversion Cycle
|
79.61 | -- | -522.82 | 259.28 | 548.59 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
